1	O
,	O
4	O
-	O
phenylenebis	O
(	O
methylene	O
)	O
selenocyanate	O
,	O
but	O
not	O
selenomethionine	O
,	O
inhibits	O
androgen	O
receptor	O
and	O
Akt	O
signaling	O
in	O
human	O
prostate	B-Cell
cancer	I-Cell
cells	I-Cell
.	O

The	O
lack	O
of	O
treatment	O
for	O
worried	O
-	O
well	O
patients	O
with	O
high	B-Pathological_formation
-	I-Pathological_formation
grade	I-Pathological_formation
prostatic	I-Pathological_formation
intraepithelial	I-Pathological_formation
neoplasia	I-Pathological_formation
combined	O
with	O
issues	O
of	O
recurrence	O
and	O
hormone	O
resistance	O
in	O
prostate	B-Cancer
cancer	I-Cancer
survivors	O
remains	O
a	O
major	O
public	O
health	O
obstacle	O
.	O

The	O
long	O
latency	O
of	O
prostate	B-Cancer
cancer	I-Cancer
development	O
provides	O
an	O
opportunity	O
to	O
intervene	O
with	O
agents	O
of	O
known	O
mechanisms	O
at	O
various	O
stages	O
of	O
disease	O
progression	O
.	O

A	O
number	O
of	O
signaling	O
cascades	O
have	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
prostate	B-Cancer
cancer	I-Cancer
development	O
and	O
progression	O
,	O
including	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
and	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
signaling	O
pathways	O
.	O

Crosstalk	O
between	O
these	O
two	O
pathways	O
is	O
also	O
thought	O
to	O
contribute	O
to	O
progression	O
and	O
hormone	O
-	O
refractory	O
prostate	B-Cancer
disease	I-Cancer
.	O

Our	O
initial	O
investigations	O
show	O
that	O
the	O
naturally	O
occurring	O
organoselenium	O
compound	O
selenomethionine	O
(	O
SM	O
)	O
and	O
the	O
synthetic	O
1	O
,	O
4	O
-	O
phenylenebis	O
(	O
methylene	O
)	O
selenocyanate	O
(	O
p	O
-	O
XSC	O
)	O
can	O
inhibit	O
human	O
prostate	B-Cell
cancer	I-Cell
cell	I-Cell
viability	O
;	O
however	O
,	O
in	O
contrast	O
to	O
SM	O
,	O
p	O
-	O
XSC	O
is	O
active	O
at	O
physiologically	O
relevant	O
doses	O
.	O

In	O
the	O
current	O
investigation	O
,	O
we	O
show	O
that	O
p	O
-	O
XSC	O
,	O
but	O
not	O
an	O
equivalent	O
dose	O
of	O
SM	O
,	O
alters	O
molecular	O
targets	O
and	O
induces	O
apoptosis	O
in	O
androgen	O
-	O
responsive	O
LNCaP	B-Cell
and	O
androgen	O
-	O
independent	O
LNCaP	B-Cell
C4	I-Cell
-	I-Cell
2	I-Cell
human	I-Cell
prostate	I-Cell
cancer	I-Cell
cells	I-Cell
.	O

p	O
-	O
XSC	O
effectively	O
inhibits	O
AR	O
expression	O
and	O
transcriptional	O
activity	O
in	O
both	O
cell	B-Cell
lines	I-Cell
.	O

p	O
-	O
XSC	O
also	O
decreases	O
Akt	O
phosphorylation	O
as	O
well	O
as	O
Akt	O
-	O
specific	O
phosphorylation	O
of	O
the	O
AR	O
.	O

Inhibition	O
of	O
Akt	O
,	O
however	O
,	O
does	O
not	O
fully	O
attenuate	O
p	O
-	O
XSC	O
-	O
mediated	O
downregulation	O
of	O
AR	O
activity	O
,	O
suggesting	O
that	O
inhibition	O
of	O
AR	O
signaling	O
by	O
p	O
-	O
XSC	O
does	O
not	O
occur	O
solely	O
through	O
alterations	O
in	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
survival	O
pathway	O
.	O

Our	O
data	O
suggest	O
that	O
p	O
-	O
XSC	O
inhibits	O
multiple	O
signaling	O
pathways	O
in	O
prostate	B-Cancer
cancer	I-Cancer
,	O
likely	O
accounting	O
for	O
the	O
downstream	O
effects	O
on	O
proliferation	O
and	O
apoptosis	O
.	O

